FY2029 Earnings Forecast for Adagene Issued By HC Wainwright

Adagene Inc. (NASDAQ:ADAG) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Adagene in a report issued on Monday, January 27th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($0.56) for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.65) per share.

Adagene Stock Up 1.1 %

Shares of ADAG stock opened at $1.87 on Tuesday. The stock has a fifty day moving average price of $2.04 and a 200 day moving average price of $2.40. Adagene has a 1 year low of $1.74 and a 1 year high of $4.29.

Institutional Investors Weigh In On Adagene

Several institutional investors and hedge funds have recently made changes to their positions in the business. Exome Asset Management LLC increased its holdings in Adagene by 74.1% during the 3rd quarter. Exome Asset Management LLC now owns 262,625 shares of the company’s stock valued at $583,000 after acquiring an additional 111,749 shares in the last quarter. Mill Creek Capital Advisors LLC acquired a new stake in shares of Adagene in the third quarter valued at approximately $202,000. Finally, Catalina Capital Group LLC increased its stake in shares of Adagene by 129.2% during the 4th quarter. Catalina Capital Group LLC now owns 29,198 shares of the company’s stock worth $58,000 after purchasing an additional 16,461 shares in the last quarter. 9.51% of the stock is currently owned by hedge funds and other institutional investors.

Adagene Company Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.